P/E ratio for Agios Pharmaceuticals (AGIO)
P/E ratio as of May 2024 (TTM): -8.86
According to Agios Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.86076. At the end of 2022 the company had a P/E ratio of -6.62.
P/E ratio history for Agios Pharmaceuticals from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -6.62 | -548.09% |
| 2021 | 1.48 | -116.17% |
| 2020 | -9.14 | 31.52% |
| 2019 | -6.95 | -9.11% |
| 2018 | -7.65 | -9.85% |
| 2017 | -8.48 | 2.65% |
| 2016 | -8.26 | -60.16% |
| 2015 | -20.7 | -70.75% |
| 2014 | -70.9 | 389.02% |
| 2013 | -14.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 15.5 | -275.47% | 🇺🇸 USA |
 Eli Lilly LLY | 142 | -1,702.91% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 12.8 | -244.69% | 🇬🇧 UK |
 Xencor XNCR | -10.5 | 18.45% | 🇺🇸 USA |
 Exelixis EXEL | 74.9 | -945.73% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 98.8 | -1,215.58% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.